BTNL2 gene variant and sarcoidosis
Sarcoidosis is an inflammatory granulomatous disorder that primarily affects the lungs and lymph nodes. Other organs such as the brain, eyes, heart, and skin can also be affected. The disease is characterised by non-caseating granulomas and an exaggerated cellular immune response caused by increased inflammatory activity. 1 The course of the disease is acute and mild in approximately 20% of all patients. In most patients a chronic stage develops which can lead to lung fibrosis. Although the exact pathogenesis of sarcoidosis remains unclear, familial clustering of the disease and the increased risk of relatives to develop sarcoidosis suggest that there might be a genetic predisposition to develop the disease. 2 A significant association was recently reported in Germany between sarcoidosis and a frequent single nucleotide polymorphism (SNP) in the BTNL2 gene, rs2076530.
3
BTNL2 is a member of the immunoglobulin gene family and is related to CD80 and CD86 co-stimulatory receptors, although its exact function is unknown. 4 BTNL2 is located on chromosome 6p21.3 in close proximity to the HLA gene cluster. rs2076530 is located at position 1 of the donor splice site in intron 5 and the associated A allele causes the usage of an alternative donor site leading to a 4 bp deletion at the mRNA level, frameshift, and premature truncation at the protein level. 3 The rs2076530 SNP alone was also associated with sarcoidosis in a case-control study of white American subjects. 4 No replication of the BTNL2 rs2076530 susceptibility to sarcoidosis has yet been studied in an independent German case-control study. We therefore performed a case-control association study in 210 patients with sarcoidosis and 202 controls. Written informed consent was given by each participant and the study was approved by the ethics committee of Bonn University School of Medicine.
The diagnosis of sarcoidosis was based on evidence of non-caseating epitheloid cell granuloma in biopsy specimens and chest radiographic abnormalities. Different stages were defined as previously described. 5 A chronic course was defined as disease over at least 2 years or at least two episodes in a lifetime. Acute sarcoidosis was defined as one episode of acute sarcoidosis which had totally resolved at the date of the examination. None of the individuals in the control group (healthy white German subjects of mean age 38.32 (15.53) years) had a history of lung disease or showed any symptoms of lung or other disease by chest radiography or laboratory blood tests. Genotyping of rs207653 was performed using the Taqman technique with a commercially available assay (Applied Biosystems, Germany). SPSS Version 12 was used for statistical analysis. The genotype distributions in the cohort were in accordance with the Hardy-Weinberg equilibrium.
The A allele frequency of rs2076530 was significantly increased in sarcoidosis patients compared with controls (A = 0.6929, G = 0.3071 in cases; A = 0.6188, G = 0.3812 in controls). It was significantly associated with an increased risk of sarcoidosis in codominant and dominant models (OR 2.31 (95% CI 1.27 to 4.23); p,0.006, table 1), but not in a recessive model (p = 0.276). The calculated population attributable risk (PAR) for AA homozygotes and AG heterozygotes was 34.6%. Our results were in accordance with the reported association between BTNL2 and sarcoidosis and replicated the finding that A allele carriers of rs2076530 have a more than twofold increased risk of developing sarcoidosis compared with GG homozygotes in the German population.
We also examined whether this increased risk is present in both chronic and acute forms of sarcoidosis. Interestingly, we found that the chronic form-but not the acute form-was significantly associated with the A allele in codominant and dominant models (OR 2.87 Normal ranges and units are in brackets. ''Normal'' peak cortisol level following hypoglycaemia .550 nmol/l. When more than one value is quoted, the tests were performed on different days. (95% CI 1.29 to 6.42), p,0.0069; table 1) with a PAR for AA homozygotes and AG heterozygotes of 50%.
This study underlines the importance of the association of BTNL2 rs2076530 variant with the susceptibility to develop sarcoidosis in a German population. Furthermore, our data suggest that susceptibility is preferentially towards the chronic form of the disease. 
Asthma and allergies in Germany
We read the study by Zöllner and colleagues published recently in Thorax about the levelling off of asthma and allergies among children in Germany between 1992 and 2001. 1 We have published a study looking at the same issue and using a similar protocol (ISAAC) 2 to assess the symptoms, diagnosis, and severity of asthma and allergies in more than 15 000 children aged 6-7 and 13-14 years between 1995 and 2000 in Münster, Germany. 3 We found a tendency towards an increase in current symptoms of asthma and allergies in both age groups, but more so among girls. 3 Indices of diagnosis either remained the same or increased in parallel with the increase in symptoms, arguing against a change in diagnostic behaviour as an explanation for our results. Indices of severity also showed a homogenous increase in the 5 year study period, pointing towards an increase in the overall burden of asthma and allergies within the society. 3 Regrettably, these results, coming from Germany, were not considered in either the discussion of Zöllner's report or in the affirmative title that no increase in asthma and allergies occurred in Germany in the 1990s. Even more regrettable is the fact that when our study was alluded to in the discussion and conclusion of the paper by Zöllner et al, it was cited-contrary to our results-as one of the studies showing a decrease or levelling off of asthma and allergies among children.
